Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma

Hepatology Research

Volumn 40, Issue 5, 2010, Pages 477-485

  Yasuda, Eisuke ^a,e   Kumada, Takashi ^a,e   Toyoda, Hidenori ^a,e   Kaneoka, Yuji ^b,e   Maeda, Atsuyuki ^b,e   Okuda, Seiji ^a,e   Yoshimi, Naoki ^c,e   Kozawa, Osamu ^d,e  

^a Department of Medical Technology ^*  (Japan)

^b OGAKI MUNICIPAL HOSPITAL   (Japan)

^c UNIVERSITY OF THE RYUKYUS   (Japan)

^d GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e FUJIFILM Wako Pure Chemical Corporation   (Japan)

Author keywords

ELISA; Glypican 3; Hepatocellular carcinoma; Immunohistochemistry; Tumor marker

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; GLYPICAN 3; GLYPICAN 3 ANTIBODY; PROTEIN ANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC LIVER DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SEROLOGY;

EID: 77954381001     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00624.x     Document Type: Article

References (37)

1. Parkin D, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2002, 55:74-108.
2. Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res 2007, 37:S95-100.
3. Zaman SN, Melia WM, Johnson RD, Portmann BC, Johnson PJ, Williams R. Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients. Lancet 1985, 1:1357-60.
4. Poynard T, Aubert A, Lazizi Y. Independent risk factors for hepatocellular carcinoma in French drinkers. Hepatology 1991, 13:896-901.
5. Colombo M, de Franchis R, Ninno ED. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991, 325:675-80.
6. Tsukuma H, Hiyama T, Tanaka S. The factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993, 328:1797-801.
7. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 1999, 31:133-41.
8. Abelev GI. Production of embryonal serum alpha-globulin by hepatomas: review of experimental and clinical data. Cancer Res 1968, 28:1344-50.
9. O'Connor GI, Tatarinov YS, Abelev GI, Uriel J. A collaborative study for the evaluation of a serologic test for primary liver cancer. Cancer 1970, 25:1091-8.
10. Di Bisceglie AM, Hoofnagle JH. Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. Cancer 1989, 64:2117-20.
11. Di Bisceglie AM, Sterling RK, Chung RT. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005, 43:434-41.
12. Taketa K, Sekiya C, Namiki M. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology 1990, 99:508-18.
13. Taketa K, Endo Y, Sekiya C. A collaborative study for the evaluation of lectin-reactive a-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 1993, 53:5419-23.
14. Oka H, Saito A, Ito K. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive a-fetoprotein. J Gastroenterol Hepatol 2001, 16:1378-83.
15. Liebman HA. Isolation and characterization of a hepatoma-associated abnormal (des-gamma carboxy) prothrombin. Cancer Res 1989, 49:6493-7.
16. Okuda H, Obata H, Nakanishi T, Furukawa R, Hashimoto E. Production of abnormal prothrombin (des-gamma-carboxy prothrombin) by hepatocellular carcinoma. A clinical and experimental study. J Hepatol 1987, 4:357-63.
17. Yano Y, Yamashita F, Kuwaki K. Clinical features of hepatitis C virus-related hepatocellular carcinoma and their association with alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II. Liver Int 2006, 26:789-95.
18. Toyoda H, Kumada T, Kiriyama S. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006, 4:111-17.
19. Filmus J, Church J, Buick R. Isolation of a cDNA corresponding to a developmentally regulated transcript in rat intestine. Mol Cell Biol 1988, 8:4243-9.
20. Filmus J, Selleck S. Glypicans: proteoglycans with a suprise. J Clin Invest 2001, 108:497-501.
21. Bernfield M, Gotte M, Park P. Function of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999, 68:729-77.
22. Libbrecht L, Severi T, Cassiman D. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 2006, 30:1405-11.
23. Tommaso LD, Franchi G, Park Y. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007, 45:725-34.
24. Wang H, Anatelli F, Zhai Q, Adley B, Chuang S, Yang X. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Arch Pathol Lab Med 2008, 132:1723-8.
25. Capurro M, Wanless I, Sherman M. Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003, 125:89-97.
26. Nakatsura T, Yoshitake Y, Senju S. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003, 306:16-25.
27. Hippo Y, Watanabe K, Watanabe A. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004, 64:2418-23.
28. Torzilli G, Minagawa M, Takayama T. Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 1999, 30:889-93.
29. Kudo M. Imaging diagnosis of hepatocellular carcinoma and premalignant/ borderline lesions. Semin Liver Dis 1999, 19:297-309.
30. Katoh H, Nakamura K, Tanaka T, Satomura S, Matsuura S. Automatic and simultaneous analysis of Lens culinaris agglutinin-reactive alpha-fetoprotein ratio and total alpha-fetoprotein concentration. Anal Chem 1998, 70:2110-14.
31. Yamagata Y, Katoh H, Nakamura K, Tanaka T, Satomura S, Matsuura S. Determination of alpha-fetoprotein concentration based on liquid-phase binding assay using anion exchange chromatography and sulfated peptide introduced antibody. J Immunol Methods 1998, 212:161-8.
32. Okuda H, Nakanishi T, Takatsu K. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity. Cancer 1999, 85:812-18.
33. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer 2003, Liver cancer Study Group of Japan, English edn., Tokyo, Kanehara & Co
34. Wang X, Degos F, Dubois S. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol 2006, 37:1435-41.
35. Shirakawa H, Suzuki H, Shimomura M. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 2009, 100:1403-7.
36. Beale G, Chattopadhyay D, Gray J. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer 2008, 8:200.
37. Capurro M, Filmus J. Glypican-3 as a serum marker for hepatocellular carcinoma. Cancer Res 2005, 65:372-3.